These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis. Foley JF; Defer G; Ryerson LZ; Cohen JA; Arnold DL; Butzkueven H; Cutter GR; Giovannoni G; Killestein J; Wiendl H; Li K; Dsilva L; Toukam M; Ferber K; Sohn J; Engelman H; Lasky T Neurol Neuroimmunol Neuroinflamm; 2024 Dec; 11(6):e200321. PubMed ID: 39393045 [TBL] [Abstract][Full Text] [Related]
3. John Cunningham Virus Status, Seroconversion Rate, and the Risk of Progressive Multifocal Leukoencephalopathy in Polish John Cunningham Virus-Seronegative Patients with Relapsing-Remitting Multiple Sclerosis. Kapica-Topczewska K; Collin F; Tarasiuk J; Czarnowska A; Chorąży M; Mirończuk A; Kochanowicz J; Kułakowska A Eur Neurol; 2020; 83(5):487-492. PubMed ID: 33027785 [TBL] [Abstract][Full Text] [Related]
4. Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations. van Kempen ZL; Leurs CE; Vennegoor A; Wattjes MP; Rispens T; Uitdehaag BM; Killestein J Mult Scler; 2017 Jun; 23(7):995-999. PubMed ID: 28112019 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing. Foley JF; Goelz S; Hoyt T; Christensen A; Metzger RR Mult Scler Relat Disord; 2019 Jun; 31():65-71. PubMed ID: 30939392 [TBL] [Abstract][Full Text] [Related]
6. Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment. Barroso B; Miquel M; Marasescu R; Demasles S; Krim E; Bonnan M Mult Scler Relat Disord; 2015 Jul; 4(4):380-2. PubMed ID: 26195060 [TBL] [Abstract][Full Text] [Related]
15. Which is the best PML risk stratification strategy in natalizumab-treated patients affected by multiple sclerosis? Prezioso C; Zingaropoli MA; Iannetta M; Rodio DM; Altieri M; Conte A; Vullo V; Ciardi MR; Palamara AT; Pietropaolo V Mult Scler Relat Disord; 2020 Jun; 41():102008. PubMed ID: 32087593 [TBL] [Abstract][Full Text] [Related]
16. Long-term safety evaluation of natalizumab for the treatment of multiple sclerosis. Clerico M; Artusi CA; Di Liberto A; Rolla S; Bardina V; Barbero P; De Mercanti SF; Durelli L Expert Opin Drug Saf; 2017 Aug; 16(8):963-972. PubMed ID: 28641055 [TBL] [Abstract][Full Text] [Related]
17. sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients. Valentino P; Malucchi S; Martire S; Bava CI; Capobianco MA; Bertolotto A Mult Scler Relat Disord; 2022 Nov; 67():104176. PubMed ID: 36126541 [TBL] [Abstract][Full Text] [Related]
18. Early reduction of the splicing factor2/alternative splicing factor: a cellular inhibitor of the JC polyomavirus in natalizumab-treated MS patients long before developing progressive multifocal leukoencephalopathy. Piu C; Ibba G; Bertoli D; Capra R; Uleri E; Serra C; Imberti L; Dolei A J Neurovirol; 2020 Feb; 26(1):133-137. PubMed ID: 31468472 [TBL] [Abstract][Full Text] [Related]
19. Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. Gelissen LMY; Loveless S; Toorop AA; Howlett J; Loeff FC; Rispens T; Killestein J; Tallantyre EC; van Kempen ZLE Mult Scler Relat Disord; 2024 Oct; 90():105796. PubMed ID: 39096666 [TBL] [Abstract][Full Text] [Related]
20. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action. Balasa RI; Simu M; Voidazan S; Barcutean LI; Bajko Z; Hutanu A; Simu I; Maier S CNS Neurol Disord Drug Targets; 2017; 16(9):1018-1026. PubMed ID: 28782487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]